drugset
Drugs / Allogeneic cytomegalovirus-specific T cells
last change Oct 2025 re-read 3 minutes ago

Allogeneic cytomegalovirus-specific T cells

Cell therapy

Developed for
glioblastoma
Investigated by
Austin Hospital, Melbourne Australia · CUREator · Merck Sharp & Dohme LLC · Princess Alexandra Hospital, Brisbane, Australia · Queensland Institute of Medical Research · Royal Brisbane and Women's Hospital
+1 more · The Newro Foundation

Trials 1

today NCT06157541 · Ph 1/2
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06157541 Feb 2024 → Oct 2025 overdue glioblastoma Queensland Institute of Medical Research Active not recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Allogeneic cytomegalovirus-specific T cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT06157541 ↗
Modality Cell therapy “Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors” NCT06157541 ↗